StevenR.HaysMD
Pulmonology • San Francisco, CACritical Care Medicine, Cystic Fibrosis, Interstitial Lung Diseases, Lung Transplantation Medicine
Professor of Medicine, Medical Director Lung Transplantation, UCSF School of Medicine
Dr. Hays is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2961Fax+1 415-353-2568
Summary
- Dr. Steven Hays is a pulmonologist in San Francisco, CA and is affiliated with UCSF Medical Center. He received his medical degree from University of Kansas School of Medicine and underwent his specialty training at UCSF and Stanford Medical Center. He has been in practice for 22 years and specializes in lung transplantation medicine, cystic fibrosis, interstitial lung diseases, and alpha-1 anti-trypsin deficiency.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2004
University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 1999 - 2003
University of Kansas School of MedicineChief Residency, Internal Medicine, 1998 - 1999- University of Kansas School of MedicineResidency, Internal Medicine, 1995 - 1998
- University of Kansas School of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 1999 - 2025
OR State Medical License 2015 - 2025- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) Start of enrollment: 2013 Jul 01
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Start of enrollment: 2019 Mar 29
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Start of enrollment: 2019 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- 143 citationsDoes Chronic Microaspiration Cause Idiopathic Pulmonary FibrosisJoyce S. Lee, Harold R. Collard, Ganesh Raghu, Matthew P. Sweet, Steven R. Hays
The American Journal of Medicine. 2010-04-01 - 80 citationsA Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM).Samuel V Kemp, Dirk-Jan Slebos, Alan Kirk, Malgorzata Kornaszewska, Kris Carron
American Journal of Respiratory and Critical Care Medicine. 2017-12-15 - 203 citationsA Multicenter RCT of Zephyr® Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)Gerard J. Criner, Richard Sue, Shawn Wright, Mark T. Dransfield, Hiram Rivas-Perez
American Journal of Respiratory and Critical Care Medicine. 2018-05-22
Journal Articles
- Genotypes Associated with Tacrolimus Pharmacokinetics Impact Clinical Outcomes in Lung Transplant RecipientsSteven R. Hays, Hilary Faust, Jonathan P. Singer, Clinical Transplantation
Press Mentions
How Digital Health Is Making UCSF's Lung Transplant Program More AccessibleJune 11th, 2021
Grant Support
- Mechanisms Of Gland Proliferation In COPDNational Heart, Lung, And Blood Institute2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
